Raymond James Financial
LTRN icon

Raymond James Financial’s Lantern Pharma LTRN Stock Holding History

Raymond James Financial’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,730
Closed -$8.63K – 5966
2025
Q2 		$8.63K Buy
+2,730
New +$9.21K ﹤0.01% 5979

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James Financial's LTRN Position: Q3 2025 in Review

Raymond James Financial sold out of Lantern Pharma (LTRN) in Q3 2025, closing a stake of 2,730 shares — an estimated $8.63K sold.

Raymond James Financial first reported a position in LTRN in Q2 2025 and held it in 1 quarter. The position peaked at $8.63K in Q2 2025. 30 funds tracked by Wall St. Rank hold LTRN as of Q3 2025.

  • Raymond James Financial reported no remaining Lantern Pharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,730 Lantern Pharma shares in Q3 2025, an estimated $8.63K.
  • Raymond James Financial first reported a position in Lantern Pharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Lantern Pharma position peaked at $8.63K in Q2 2025.
  • 30 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.